China’s National Medical Products Administration (NMPA) has approved two innovative medicines. The NMPA granted conditional approval under priority review to a Category‑1 innovative drug developed by Yaojie Ankang (Nanjing) Technology Co., Ltd., marketed as Jientai, for adults with advanced, metastatic or unresectable cholangiocarcinoma harboring FGFR2 fusions or rearrangements who have previously received systemic therapy and FGFR inhibitor treatment. Separately, the NMPA approved Jichuan Pharm

China’s National Medical Products Administration (NMPA) has approved two innovative medicines. The NMPA granted conditional approval under priority review to a Category‑1 innovative drug developed by Yaojie Ankang (Nanjing) Technology Co., Ltd., marketed as Jientai, for adults with advanced, metastatic or unresectable cholangiocarcinoma harboring FGFR2 fusions or rearrangements who have previously received systemic therapy and FGFR inhibitor treatment. Separately, the NMPA approved Jichuan Pharmaceutical Group Co., Ltd.’s pediatric laxative granules as a TCM 1.1‑class innovative drug; this is the first post‑Regulation TCM innovative product approved with a syndrome‑based pediatric constipation indication (food‑accumulation pattern).